5.06
Personalis Inc 주식(PSNL)의 최신 뉴스
Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy - MSN
Personalis reveals ctDNA test predicts cervical cancer relapse - Investing.com Australia
Personalis reveals ctDNA test predicts cervical cancer relapse By Investing.com - Investing.com Canada
Personalis (PSNL) Blood Test Shows Promise in Detecting Cervical Cancer Early | PSNL Stock News - GuruFocus
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO - Yahoo Finance
Personalis Says Studies Show NeXT Personal Test Could Identify Relapse Risk in Breast Cancer Patients - marketscreener.com
Personalis (PSNL) Showcases Promising Results for NeXT Personal in Breast Cancer Care | PSNL Stock News - GuruFocus
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse - Yahoo Finance
Northern Trust Corp Lowers Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Millennium Management LLC Has $7.61 Million Stock Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
BNP Paribas Financial Markets Acquires 71,721 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis and Academic Partners to Present Latest Data on Ultra - GuruFocus
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection - Yahoo Finance
Personalis Holds Virtual Annual Stockholders Meeting - TipRanks
PSNL to Discuss Future Plans in Upcoming Virtual Meeting | PSNL Stock News - GuruFocus
Brokerages Set Personalis, Inc. (NASDAQ:PSNL) PT at $8.00 - Defense World
Personalis Inc (PSNL): A Sitting Duck With -162.63% Upside Potential - Stocksregister
Guggenheim Begins Coverage on Personalis (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Stake Raised by Jane Street Group LLC - Defense World
Jane Street Group LLC Has $2.32 Million Stock Holdings in Personalis, Inc. (NASDAQ:PSNL) - The AM Reporter
Personalis, Inc. (NASDAQ:PSNL) Shares Acquired by Stifel Financial Corp - Defense World
Guggenheim Initiates Buy Rating for Personalis (PSNL) with $6 Ta - GuruFocus
Guggenheim starts Personalis with a Buy, cites ‘best-in-class infrastructure’ - TipRanks
Guggenheim Initiates Buy Rating for Personalis (PSNL) with $6 Target | PSNL Stock News - GuruFocus
Guggenheim Initiates Personalis at Buy With $6 Price Target - marketscreener.com
Guggenheim Starts Coverage on Personalis (PSNL) with Buy Rating - GuruFocus
Guggenheim Starts Coverage on Personalis (PSNL) with Buy Rating | PSNL Stock News - GuruFocus
Dimensional Fund Advisors LP Purchases 242,141 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Raymond James Financial Inc. Takes Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Leading Genomics Company Personalis Takes Center Stage at Major Craig-Hallum Investor Conference - Stock Titan
Personalis stock price target raised to $9 at H.C. Wainwright By Investing.com - Investing.com Nigeria
What is HC Wainwright’s Estimate for Personalis Q2 Earnings? - Defense World
Personalis reiterates 2025 revenue guidance of $80M-$90M with focus on MRD testing growth - MSN
HC Wainwright Raises Personalis (NASDAQ:PSNL) Price Target to $9.00 - Defense World
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - MSN
Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth - Yahoo Finance
Barclays PLC Acquires 43,900 Shares of Personalis, Inc. (NASDAQ:PSNL) - The AM Reporter
JPMorgan Chase & Co. Has $34,000 Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Barclays PLC Increases Stock Holdings in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis stock price target raised to $9 at H.C. Wainwright - Investing.com Australia
Personalis Inc.: Strong Financial Performance and Promising Future Prospects Drive Buy Rating - TipRanks
Will Personalis' Testing Growth And MRD Strategy Pay Off In 2025? - Nasdaq
Analyst Expectations For Personalis's Future - Benzinga
Personalis, Inc. (NASDAQ:PSNL) Q1 2025 Earnings Call Transcript - Insider Monkey
Personalis (PSNL) Receives Price Target Boost from Analyst | PSNL Stock News - GuruFocus
H.C. Wainwright Increases Price Target for Personalis (PSNL) to $9 | PSNL Stock News - GuruFocus
Personalis Reports Strong Q1 Growth in Genomics - TipRanks
Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... - Yahoo Finance
Earnings call transcript: Personalis beats Q1 2025 earnings, stock rises By Investing.com - Investing.com South Africa
Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong R - GuruFocus
Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... By GuruFocus - Investing.com Canada
Personalis Reports First Quarter 2025 Financial Results - BioSpace
Personalis: Q1 Earnings Snapshot - CTPost
Personalis (PSNL) Q1 2025 Earnings Reflects Strong Growth in Molecular Tests - GuruFocus
Personalis (PSNL) Q1 2025 Earnings Reflects Strong Growth in Mol - GuruFocus
자본화:
|
볼륨(24시간):